Fibryga’s New FDA Approval: A Triumph For Fibrinogen Care
The FDA has expanded the indication of Octapharma’s Fibryga to include AFD. This makes it the first and only on-demand, virus-inactivated, human plasma-derived fibrinogen concentrate approved for this indication. This expanded indication marks a turning point in managing severe bleeding episodes. It provides fast, more accurate treatment about the currently used standard of care, cryoprecipitate….